Sam Brusco, Associate Editor05.16.23
Bioretec, a pioneer in bioresorbable orthopedic implants, has brought Dr. Jeremy Dublon to its team as a regulatory advisor to support the company’s U.S. commercialization strategy from both a clinical and regulatory perspective.
Dr. Dublon is a board-certified pediatric surgeon who specializes in foot and ankle diagnosis and treatment in people of all ages. He also has training and education in podiatric medicine, surgery, and orthopedics.
He previously served at the U.S. Food and Drug Administration (FDA) on the review team as a medical officer in the Division of Restorative, Repair, and Trauma evaluating orthopedic products. He was also a deputy service chief at Walter Reed National Military Medical Center, where he led the podiatry department and acted as White House medical consultant and surgeon to the President.
Dr. Dublin participates in supporting the company’s RemeOs trauma screw launch, indication expansion, and commercialization from clinical and regulatory perspectives. RemeOs gained FDA market authorization in March 2023.
"We warmly welcome Dr. Dublon into our team with his extensive background from the field of orthopedics. His clinical expertise in foot and ankle surgery and his broad experience of the U.S. regulatory processes will strongly support our future success in the vast U.S. markets," Timo Lehtonen, CEO of Bioretec told the press.
Dr. Dublon is a board-certified pediatric surgeon who specializes in foot and ankle diagnosis and treatment in people of all ages. He also has training and education in podiatric medicine, surgery, and orthopedics.
He previously served at the U.S. Food and Drug Administration (FDA) on the review team as a medical officer in the Division of Restorative, Repair, and Trauma evaluating orthopedic products. He was also a deputy service chief at Walter Reed National Military Medical Center, where he led the podiatry department and acted as White House medical consultant and surgeon to the President.
Dr. Dublin participates in supporting the company’s RemeOs trauma screw launch, indication expansion, and commercialization from clinical and regulatory perspectives. RemeOs gained FDA market authorization in March 2023.
"We warmly welcome Dr. Dublon into our team with his extensive background from the field of orthopedics. His clinical expertise in foot and ankle surgery and his broad experience of the U.S. regulatory processes will strongly support our future success in the vast U.S. markets," Timo Lehtonen, CEO of Bioretec told the press.